Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Triple Negative Breast Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Breast Neoplasms, Male 5Brain Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3HER2-positive Advanced Breast Cancer 3Advanced Breast Cancer 3Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Lung Neoplasms 2HER2-negative Breast Cancer 2HER2 Positive Breast Cancer 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Recurrence 1Primary Breast Cancer 1Pheochromocytoma 1Patient Acceptance of Health Care 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Metastatic HER2-positive Breast Cancer 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive Advanced Breast Cancer 1

Interventions

liposomal doxorubicin 1Vinorelbine 1Surveys and Questionnaires 1Prophylactic Mastectomy 1Docetaxel 1Cognitive Behavioral Therapy 1Cephalexin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Predisposition to Disease × Vinorelbine × Breast × Clear all
NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
300 enrolled
Breast

Breast Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡